Company / SG&A Expense
Vistagen Therapeutics, Inc. SG&A Expense History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$13.5M
FY2023
5-year range
$6.3M / $13.9M
FY2019-FY2023
Trend
+89.9%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 8 years, ranging from $4M in FY2014 to $14M in FY2017.
Based on SEC 10-K filings.
$13M in FY2023 with a 5-year CAGR of +16.5%.
Increased from $7M to $13M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +16.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +16.5%, indicating consistent growth.
- In FY2023, sg&a expense increased 89.9% year-over-year.
- Peak sg&a expense was recorded in FY2017.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $13.5M | +89.9% |
| FY2022 | $7.1M | -4.4% |
| FY2021 | $7.4M | +18.0% |
| FY2018 | $6.3M | -54.8% |
| FY2017 | $13.9M | +290.7% |
| FY2014 | $3.6M | -28.7% |
| FY2012 | $5.0M | +0.8% |
| FY2011 | $5.0M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026